Abstract
Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 287-294 |
| Number of pages | 8 |
| Journal | Journal of Clinical Gastroenterology |
| Volume | 52 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
Keywords
- direct-acting antiviral therapy
- hepatitis C
- kidney transplant
- renal insufficiency
ASJC Scopus subject areas
- Gastroenterology
Cite this
Management of Chronic Hepatitis C in End-stage Renal Disease. / Angulo-Diaz, Veronica; Lim, Joseph K.; Martin, Paul; Liapakis, Ann Marie.
In: Journal of Clinical Gastroenterology, Vol. 52, No. 4, 01.01.2018, p. 287-294.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Management of Chronic Hepatitis C in End-stage Renal Disease
AU - Angulo-Diaz, Veronica
AU - Lim, Joseph K.
AU - Martin, Paul
AU - Liapakis, Ann Marie
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.
AB - Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.
KW - direct-acting antiviral therapy
KW - hepatitis C
KW - kidney transplant
KW - renal insufficiency
UR - http://www.scopus.com/inward/record.url?scp=85044296622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044296622&partnerID=8YFLogxK
U2 - 10.1097/MCG.0000000000000941
DO - 10.1097/MCG.0000000000000941
M3 - Review article
VL - 52
SP - 287
EP - 294
JO - Journal of Clinical Gastroenterology
JF - Journal of Clinical Gastroenterology
SN - 0192-0790
IS - 4
ER -